The patient in this case is a beneficiary of the combined application of anti-tumor drugs with different mechanisms and also provides a clinical example for enhancing the immune anti-tumor effect of PD-1 inhibitor combined with radiotherapy. The gene discussed is PDCD1; the disease is neoplasm.